Intersections of Innovation – Our Investment in Terray Therapeutics


Terray Therapeutics announced today its $ 60 million Serie A-led round of Madrona. We have been working with the company for more than two years in a pandemic and are pleased to talk more about the company, its mission and our belief in the power of innovation.

Interesting to hear from the founders and Chris? Check out this podcast Founded & Funded, published in February 2022.

When pharmaceutical companies set out to discover new small molecules, they usually follow the same pattern: years of biological experimentation followed by a slow process of developing and testing potential drug candidates. Although some new techniques have helped improve this process, the basic steps and timelines are the same.

We believe that there is a huge untapped potential in the application of machine learning to increase the speed and accuracy of drug detection. But even the most powerful artificial intelligence cannot work with insufficient or dim data.

We believe that there is a huge untapped potential in the application of machine learning to increase the speed and accuracy of drug detection. But even the most powerful artificial intelligence cannot work with insufficient or dim data

Terray Therapeutics creates a chemical system that combines both parts of the puzzle – modern models of artificial intelligence and machine learning and the most extensive sets of chemical data in the world. Today, we are pleased to announce our major investment in their $ 60 million Series A fundraiser.

We started collaborating with founders Jacob and Eli Berlin when we invested in their opening round. Prior to founding Terray, Jacob had previously worked as a professor at the Beckman Research Institute at the Hope Complex Cancer Center in Los Angeles, developing core technology and creating the company’s early stages. The entire Madrona team was thrilled with their wet lab platform and their ability to quickly create huge chemical libraries and then test them in minutes. Since then, core technology has made rapid progress: Terray has industrialized its technology and now measures billions of accurate chemical data daily using its existing drug candidate libraries, and the company is constantly synthesizing libraries with many millions of new drug candidates – truly unprecedented. speed, scale and accuracy in the world of biotechnology. Thanks to its core technology, Terray is turning the process of detecting low-bandwidth drugs into a data-driven machine learning problem.

By focusing on the scale and quality of its data, Terray allows you to develop drugs based on artificial intelligence. The team applies ML to each startup screening, comparing each chemical compound to potential causes of disease and creating an in-depth understanding of billions of interactions. An integrated approach to wet lab and artificial intelligence is key to the power of the platform and helps close the data science cycle with real experimental data.

We believe that Terray is the key to improving drug discovery processes – its ability to generate and accurately measure new datasets allows iteration of scientific hypotheses and the ability to obtain rescue drugs with small molecules much faster than possible with traditional techniques.

At Madrona, our dissertation “Crossing Innovation” is built on combining the power of data and computer science with research in the life sciences. Combining these two disciplines creates a whole new field of biotechnology innovation. Often this means combining machine learning and innovation in a wet lab, as is the case with Terray. We believe that Terray is the key to improving drug discovery processes – its ability to generate and accurately measure new datasets allows iteration of scientific hypotheses and the ability to obtain rescue drugs with small molecules much faster than possible with traditional techniques.

For the past two years, working with the Terray team has been a joy. Brothers Jacob and Eli Berlin founded the company using their unique skills gained through decades of innovative research and finance, respectively. Since then, they have created a world-class management team with in-depth computational and experimental experience in drug discovery and development and have assembled a team of 50 world-class data and experimental scientists who are passionate about creating something that will benefit society. We couldn’t be more excited to deepen our partnership with them alongside a syndicate of world-class investors.

Terray’s vision is a symbol of why we admire our dissertation “Intersection of Innovation” and an excellent example of applying the power of modern software and machine learning to solve previously unsolvable scientific problems.

Similar ideas and podcasts

  • May 20, 2020

    (Suyal Patel and Parag Malik, co-founders of Nautilus) The code of life, biology and chemistry have been constantly evolving over millions of years. The computational code is valid for less than 100 years. Today,…

  • September 7, 2021

    We are excited to talk more about why we led the announced today round of the A-Alpha Bio Series, and congratulate David, Randolph and their team on their vision and progress to date. A-Alpha is…

  • February 17, 2022

    This week Madrona’s partner Chris Picard met with Terray Therapeutics founders (and brothers) Jacob and Eli Berlin, as well as with leading Terray scholar Narbe Mardyrosyan to talk about…

Leave a Comment